Connect with us

Hi, what are you looking for?

Jewish Business News


Teva finds double-dose Copaxone halves side-effects

A 50% reduction in adverse side-effects was reported with the three-times-a-week 40 mg MS injection.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

copaxone_05 TEVA

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has published results of a study showing less side effects in 40 mg doses of Copaxone injected three times a week as against 20 mg doses of the multiple sclerosis treatment injected daily.

The primary endpoint of the study, the adjusted mean annualized rate of injection-related adverse events (IRAEs), was achieved with a 50% reduction with the three-times-a-week 40 mg Copaxone versus the daily 20 mg regimen. In a post-hoc analysis, a similar reduction in moderate/severe IRAEs was observed with the less frequent, three-times-a-week Copaxone relative to the daily Copaxone.

Teva’s President of Global R&D and Chief Scientific Officer Dr. Michael Hayden said, “We’re pleased these results provide supportive data that fewer injections with three-times-a-week Copaxone 40 mg resulted in half as many reported IRAEs compared to the number of IRAEs with the Copaxone 20 mg once-daily dosing regimen.”




You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.